Geron Corp (GERN)
Geron is a biopharmaceutical company that sells RYTELO, a treatment for certain blood cancers. It last closed at $1.00 on Nov 17, up 6.17% on the day. The average 12-month price target from 2 analysts is $3.75 (+275.0% from the last close), with a high of $5.00 and a low of $2.50. In the past 30 days there were 1 dark pool print totaling $204K, the largest $204K.
Key Stats
Last 12 monthsNot reported for this period.
From GERN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on GERN in the past 90 days. The average target is $3.75, with a high of $5.00 and a low of $2.50, compared with the last close of $1.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | Wedbush | Maintained | Buy | $5 |
| Oct 28 | Needham | Maintained | Buy | $2.50 |
Technical Analysis
The stock is 1% below its 20 day and 16% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot at $0.99, and the nearest resistance the 20 day average at $1.01.
| RSI (14) | 44.70 | Middle of its range | Neutral |
| MACD | -0.06 | Above its signal line | Bullish |
| Stochastic | 45.9 | Middle of its range | Neutral |
| ADX (14) | 35.5 | Trending down | |
| Williams %R | -39.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -25.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +7.5% | Change over 10 sessions | Bullish |
| ATR (14) | $0.07 | Typical daily range, 7.3% of price |
| RSI (14) | 37.49 | Weak, oversold below 30 | Neutral |
| MACD | -0.11 | Below its signal line | Bearish |
| Stochastic | 18.2 | Near the bottom of its range | Oversold |
| ADX (14) | 20.8 | Weak trend | |
| Williams %R | -79.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -121.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −25.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.17 | Typical daily range, 16.8% of price |
What happened before
See how GERN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GERN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in GERN in the last 90 days.
Dark Pool
30DGERN Institutional Ownership
Full report →- ▲112 buying vs 83 selling
- ▼Held by funds -5.0 pts
- ●Funds holding -1
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 260 | 261 | −0.4% |
| In funds' top 10 | 1 | 0 | – |
| Held by funds | 70.9% | 75.9% | −5.0 pts |
| New / increased | 26 / 86 | 34 / 96 | −13.8% |
| Reduced / sold out | 59 / 24 | 60 / 30 | −7.8% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GERN is in one of them and how their past GERN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GERN in an article yet. Here's the latest on the wider market.
About Geron
Geron is a biopharmaceutical company based in Foster City, California, that develops treatments for blood cancers. Its main product is RYTELO, a telomerase inhibitor approved in the United States for adults with myelodysplastic syndrome who need frequent red blood cell transfusions. The company sells RYTELO to patients and health care providers in the U.S. and plans to make it available in select European Union markets through outside partners. It is also testing the drug in myelofibrosis, another blood cancer.
- Headquarters
- Foster City, CA
- Founded
- 1990
- Website
- geron.com ↗



